Impact BioMedical, INC. Operating Expenses
Impact BioMedical, INC. (IBO) reported Operating Expenses of $1.01 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2025-05-14
- Impact BioMedical, INC. operating expenses for the quarter ending 2025-03-31 was $1.01M, a 31.00% increase year-over-year.
- Impact BioMedical, INC. operating expenses for the quarter ending 2024-12-31 was $26.23M, a 2202.99% increase year-over-year.
- Impact BioMedical, INC. operating expenses for the quarter ending 2024-09-30 was $1.13M, a 4.55% increase year-over-year.
- Impact BioMedical, INC. operating expenses for the quarter ending 2024-06-30 was $626.00K, a 37.90% decline year-over-year.
- Impact BioMedical, INC. operating expenses for fiscal 2024 was $28.75M, a 613.83% increase from fiscal 2023.
- Impact BioMedical, INC. operating expenses for fiscal 2023 was $4.03M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2025-03-31 | $1.01M 10-Q · filed 2025-05-14 | $27.24M derived: sum of 2 quarters · filed 2025-05-14 | $28.37M derived: sum of 3 quarters · filed 2025-05-14 | $28.99M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | $26.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $27.36M derived: sum of 2 quarters · filed 2025-03-28 | $27.98M derived: sum of 3 quarters · filed 2025-03-28 | $28.75M 10-K · filed 2025-03-28 |
| 2024-09-30 | $1.13M 10-Q · filed 2024-11-12 | $1.75M derived: sum of 2 quarters · filed 2024-11-12 | $2.52M 10-Q · filed 2024-11-12 | $3.66M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | $626.00K 10-Q · filed 2024-08-13 | $1.40M 10-Q · filed 2024-08-13 | $2.54M derived: sum of 3 quarters · filed 2025-05-14 | $3.61M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | $771.00K 10-Q · filed 2025-05-14 | $1.91M derived: sum of 2 quarters · filed 2025-05-14 | $2.99M derived: sum of 3 quarters · filed 2025-05-14 | $4.00M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.22M derived: sum of 2 quarters · filed 2025-03-28 | $3.23M derived: sum of 3 quarters · filed 2025-03-28 | $4.03M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.08M 10-Q · filed 2024-11-12 | $2.09M derived: sum of 2 quarters · filed 2024-11-12 | $2.89M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.01M 10-Q · filed 2024-08-13 | $1.81M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $803.00K 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |